Litcius/Paper detail

Dual PI3K/HDAC Inhibitor BEBT-908 Exhibits Potent Efficacy as Monotherapy for Primary Central Nervous System Lymphoma

Ning Wang, Zhenxian Mo, Lu Pan, Minhua Zhou, Xiaolan Ye, Xinjian Liu, Xiong Cai, Changgeng Qian, Feili Chen, Yan Xiong, Fushun Fan, Wenyu Li

2023Targeted Oncology11 citationsDOI

Topics & Concepts

In vivoMedicinePrimary central nervous system lymphomaLymphomaCancer researchPI3K/AKT/mTOR pathwayPharmacologyBlotBrain tumorGliomaBlood–brain barrierCancerPharmacokineticsCentral nervous systemPathologySignal transductionInternal medicineBiologyBiotechnologyBiochemistryGeneCNS Lymphoma Diagnosis and TreatmentGlioma Diagnosis and TreatmentHistone Deacetylase Inhibitors Research
Dual PI3K/HDAC Inhibitor BEBT-908 Exhibits Potent Efficacy as Monotherapy for Primary Central Nervous System Lymphoma | Litcius